Can Pentoxifylline Improve Long-term Outcomes In Preterm Infants With Late-onset Sepsis Or Necrotizing Enterocolitis – A Pragmatic, Randomized, Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,901,130.00
Summary
Very preterm infants are at high risk of death and disability. Brain injury is often the result of inflammation caused by infection or bowel disease. To date, there is no treatment to reduce the harmful effects of inflammation. Pentoxifylline reduces inflammation and is a promising, safe and inexpensive treatment option for preterm infants. This study will determine whether Pentoxifylline in addition to antibiotics improves survival without disability in preterm infants.
Bio-molecular Studies For Improved Diagnosis And Management Of Australian Children With Fish Allergy
Funder
National Health and Medical Research Council
Funding Amount
$496,602.00
Summary
Allergy to fish among children is often life-long and emerging as a significant healthcare issue worldwide, while management of fish allergy is challenging due to the lack of reliable diagnostic assays. This research grant will lead to the development of novel diagnostics for fish allergy in Australia, addressing aspects of the worldwide food allergy epidemic and forms the ideal platform for the study of fish specific allergens, generating novel knowledge for greatly improved patient management.
Modified Peanut Allergen Combined With A Novel Dietary Adjuvant As A Cure For Peanut Allergy: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,130,021.00
Summary
Peanut allergy is common and there is no cure. Current studies of peanut immunotherapy have shown the effects are not generally long lasting with many side effects. We plan to study a novel form of oral peanut immunotherapy using modified peanut and a dietary fibre (modified starch) supplement. We have evidence that modified peanut may work to desensitise patients with less side effects and that the diet supplement protects animals from developing food allergy.
Randomised Controlled Trial Of The Use Of Nitazoxanide Versus Placebo To Treat Gastroenteritis Among Aboriginal Children
Funder
National Health and Medical Research Council
Funding Amount
$1,324,808.00
Summary
Better treatment strategies are needed for Indigenous children with gastroenteritis. At present, most treatment is supportive only, with little effect on the duration of symptoms. Nitazoxanide appears to have effects on a broad range of pathogens which cause gastroenteritis, but it is not clear whether it will be of benefit in this population. We will compare the speed of symptom resolution in children who receive nitazoxanide with a group who receive a placebo instead.
Does Bovine Lactoferrin Prevent Death Or Disability In Very Low Birthweight Infants? Childhood Follow Up In The NHMRC LIFT Study
Funder
National Health and Medical Research Council
Funding Amount
$1,474,012.00
Summary
Our international consortium of investigators proposes to undertake follow up in survivors among 1,500 very low birth weight preterm infants enrolled in the NHMRC Lactoferrin Infant Feeding Trial, which is designed to evaluate whether low-cost oral lactoferrin supplementation reduces death and disability in early childhood.
Rapid Ferric Carboxymaltose Infusion (Ferinject) For Iron Deficiency Anaemia In Aboriginal Children: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,236,421.00
Summary
The “Rapid Iron Infusion Project” will assess whether an intravenous infusion of ferric carboxymaltose (Ferinject) given over 15 minutes in children prior to their discharge from hospital will reduce the risk of ongoing anaemia. The potential benefits of iron infusion include higher haemoglobin levels, fewer painful iron injections over the next 6-9 months, better adherence to recommended treatment, and less use of primary health care resources.
Does Antenatal Magnesium Sulphate Given To Women At Risk Of Preterm Birth Between 30 And 34 Weeks' Gestation Reduce The Risk Of Death Or Cerebral Palsy In Their Children? - A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,978,760.00
Summary
Antenatal magnesium sulphate is recommended prior to preterm birth at less than 30 weeks’ gestation. Whether there are benefits at later gestations is uncertain. This study is assessing whether magnesium sulphate given to women at risk of very preterm birth between 30 to 34 weeks’ gestation increases the chance of their baby surviving without cerebral palsy.
Should Very Premature Babies Receive A Placental Transfusion At Birth? A Randomised Controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$2,875,774.00
Summary
Premature babies under 30 weeks gestation are up to a hundred times more likely than full term babies to die or survive with major disability, often from brain damage due to poor blood flow after birth. This randomised study will find out if giving them more placental blood at birth, by means of a delay in clamping the umbilical cord, then milking it, reduces anemia, blood transfusions, brain damage, infection, death and disability. The results may benefit millions of premature babies worldwide.